Today: 30 April 2026
Adobe stock slips in year-end trading as tech eases; ADBE investors look to 2026 catalysts
31 December 2025
1 min read

Adobe stock slips in year-end trading as tech eases; ADBE investors look to 2026 catalysts

NEW YORK, December 31, 2025, 15:42 ET — Regular session

  • Adobe shares fell about 0.6% in afternoon trading, tracking a softer tape for U.S. tech and software stocks.
  • Wall Street’s main indexes were slightly lower in holiday-thinned volumes on the final trading day of 2025, Reuters reported.
  • Investors are looking ahead to the Federal Reserve’s late-January policy meeting and Adobe’s next earnings update in March.

Adobe Inc shares were down 0.6% on Wednesday as U.S. tech stocks drifted lower in thin, year-end trading. The stock fell $2.08 to $350.43 in afternoon dealings.

The timing matters: the final session of the year is often driven by position-squaring and low liquidity, which can magnify small moves. Wall Street’s major indexes were edging lower, even as they remained set for double-digit annual gains, Reuters reported.

For Adobe, the tape action underscores how closely the stock is trading with broader software sentiment going into 2026. A software-focused ETF was down about 1.1% on the day, while the tech sector was lower as investors rotated in light volumes.

Adobe traded between $350.00 and $352.77 on the session, after opening at $350.98. About 1.2 million shares had changed hands by mid-afternoon.

Other large software names were also lower, including Autodesk, ServiceNow and Salesforce, while Microsoft slipped alongside the sector. The Nasdaq-100 proxy fund was down about 0.7%.

“It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide, commenting on the holiday-period churn in technology shares. Reuters

Reuters also flagged the absence of a typical “Santa Claus rally” — the market’s tendency to rise in the last five trading days of December and the first two of January — as 2025 wound down. U.S. markets are closed on Thursday for New Year’s Day. Reuters

Adobe has been in focus this month for its outlook and AI strategy, even if there was no fresh company-specific catalyst on Wednesday. In December, Adobe forecast fiscal 2026 revenue of $25.9 billion to $26.1 billion, above Wall Street estimates, after posting quarterly revenue of $6.19 billion.

The company has been pitching AI features as a growth driver across Creative Cloud and document tools. Adobe also integrated Photoshop, Adobe Express and Acrobat into ChatGPT earlier this month, aiming to put core functions in front of a wider audience through conversational workflows.

What investors are watching next is less about Wednesday’s ticks and more about the 2026 policy backdrop and demand trends for software spending. The Federal Reserve’s next meeting is scheduled for Jan. 27–28, Reuters reported.

For Adobe, the next major known checkpoint is its fiscal first-quarter earnings call scheduled for March 12. Traders will be looking for commentary on subscription momentum and annual recurring revenue, a key gauge of contracted subscription run-rate.

Technically, Adobe shares have been orbiting the $350 area in recent sessions, with recent closes clustering in the low-to-mid $350s. A decisive break from that range could draw more systematic flows once holiday volumes fade.

Stock Market Today

  • Eli Lilly (LLY) Shares Drop 7.6% in Week, DCF Model Suggests 40% Undervaluation
    April 29, 2026, 11:18 PM EDT. Eli Lilly's (LLY) stock price has dropped 7.6% in the past week, down 21.2% year to date despite a strong 3-year return exceeding 100%. The recent pullback prompts questions on valuation. A Discounted Cash Flow (DCF) analysis, which forecasts future free cash flows discounted to present value, estimates the stock's intrinsic value at $1,427.87, about 40.4% above the current $851.21 share price. This suggests the shares might be undervalued despite their recent decline. Conversely, Eli Lilly's price-to-earnings (P/E) ratio stands at 36.9, representing a premium compared to the pharmaceutical industry average of 15.9 and peers at 19.2, indicating the market prices in higher growth expectations or lower risk. Investors face a mixed picture: a substantial discount on cash flow metrics but a premium relative to earnings multiples.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
AppLovin (NASDAQ: APP) stock dips today as year-end tech pullback pressures growth names
Previous Story

AppLovin (NASDAQ: APP) stock dips today as year-end tech pullback pressures growth names

Robinhood stock slips into year-end after December trading snapshot; Barclays flags Q4 risk
Next Story

Robinhood stock slips into year-end after December trading snapshot; Barclays flags Q4 risk

Go toTop